Breast cancer roundup from ESMO 2020
Breast cancer roundup from ESMO 2020
OncoAlert and ecancer weekly roundup for September 14-19, 2020
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer
Latest updates to the ESMO bone health guidelines
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC
MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer
Personalised molecularly matched therapies for carcinomas of unknown primary
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer
Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC
The emerging importance of studying immune regulatory molecule expression patterns